Mounjaro®
Starting from £179.99/mo
Start journey Learn moreThere is no licensed 30mg tirzepatide pre-filled pen in the UK. The highest strength available is 15mg per pen, and treatment always begins at 2.5mg under clinical supervision. If you've seen a 30mg figure online, it most likely refers to the total amount of tirzepatide in a four-dose KwikPen (4 × 7.5mg, for example) rather than a single injection. These are prescription-only medicines; a GPhC-registered prescriber decides which dose is clinically appropriate for each person before anything is dispensed.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Every Mounjaro KwikPen is a multi-dose device that delivers four weekly injections from a single cartridge. That means a 7.5mg pen, for instance, contains 30mg of tirzepatide in total, four shots of 7.5mg each. This is almost certainly where a search for "30mg tirzepatide pen" originates: somebody has seen the total cartridge content on the label or packaging and assumed it reflects a single dose.
The six licensed UK strengths (2.5, 5, 7.5, 10, 12.5 and 15mg) refer to the amount delivered per individual injection, not to the full pen. The NHS medicines page for tirzepatide explains this clearly: the pen is dialled to the correct strength, and each of the four injections it contains delivers that same amount. Once all four doses are used, the pen is finished and disposed of in a sharps container.
No 30mg single-dose pen exists in the UK or European licensing framework. If a website is advertising one, that is a serious red flag about the legitimacy of the source.
Treatment starts at 2.5mg, a dose whose job is to help your body adjust to the medicine rather than to produce significant weight loss. Most people move to 5mg after four weeks, then the prescriber reviews progress before each subsequent step: 7.5mg, 10mg, 12.5mg and, if needed and tolerated, 15mg. NICE's appraisal of tirzepatide (TA1026) describes the clinical rationale for this graduated approach, and the schedule is grounded in the SURMOUNT-1 trial data that showed average body-weight reductions of around 20–21% at the highest dose over 72 weeks.
Crucially, not everyone needs or reaches 15mg. The prescriber's aim is the lowest dose that achieves good tolerability and meaningful progress. If someone is doing well at 10mg, staying there is a valid clinical decision. Speeding through the schedule to reach a higher number is not the goal, and no one should be adjusting doses without clinical guidance.
If you're curious about what a specific step along that path involves, the detail on 5mg tirzepatide or the 2.5mg starter dose covers what to expect at those stages.
Because each pen lasts four weeks, storage matters throughout that whole period. The pen lives in the fridge (ideally somewhere accessible, like the door shelf) between injections, kept at 2–8°C. Once removed, there is a limited window during which it can be kept at room temperature, but the exact duration is specified in the Patient Information Leaflet and varies by strength; always check your leaflet rather than relying on a general figure. This is one reason the multi-dose pen format is practical: the pen returns to the fridge after every use, rather than being a single device managed across an extended period.
Injection sites rotate across the abdomen, thigh and upper arm. After each injection the pen is recapped and refrigerated. Disposal happens at the end of the four-week cycle, or sooner if the pen is dropped or damaged, in which case the remaining doses should not be used.
For a broader look at how Mounjaro fits into a weight-management plan, the Mounjaro overview covers the full picture, from how the dual GIP and GLP-1 mechanism works to the clinical evidence and eligibility criteria.
If you've been prescribed a higher dose elsewhere and are wondering whether 30mg is an option, the short answer is that it isn't, not under any UK licence. If a seller is claiming to supply it, the medicine is either mislabelled, counterfeit, or unlicensed. The MHRA has warned repeatedly about fake weight-loss pens sold online, and some have been found to contain insulin rather than tirzepatide, with serious consequences for buyers. You can report suspect sellers at the MHRA Yellow Card service.
If your question is really about cost (whether a multi-dose pen represents good value against what the private market charges) the Mounjaro cost guide sets out what you can realistically expect to pay through a legitimate regulated pharmacy, and what headline prices often leave out. For people considering whether treatment might be suitable for them at all, a confidential free consultation is the right starting point: a prescriber reviews your full picture, recommends the appropriate starting dose, and explains the titration path from there. That clinical conversation is where dose decisions belong.
To check your eligibility and speak to one of our GPhC-registered prescribers, start your free consultation and we'll review your answers the same day.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.